Pharmaceutical industry
BioWa, a subsidiary of Kyowa Hakko Kogyo Co., Ltd., and Aphton Corporation have announced a licensing agreement for the use of BioWa's POTELLIGENT technology to develop a next-generation Lewis Y-specific antibody, IGN312. This collaboration aims to create an antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, which can
Pharmaceutical industry
Joseph A. Bellanti, MD, Director of the International Center for Interdisciplinary Studies of Immunology at Georgetown University, has joined the scientific advisory board of DelSite Biotechnologies, Inc., a Carrington Laboratories, Inc. subsidiary. Alongside Kinam Park, PhD, and Charles L. McCormick, PhD, Bellanti will advise DelSite on the clinical development of
Pharmaceutical industry
Patients undergoing percutaneous coronary intervention for peripheral vascular disease can safely benefit from adjunctive eptifibatide treatment. A single-center pilot trial conducted by K.J. Rocha-Singh and colleagues at St. John's Hospital in Springfield evaluated the safety and feasibility of eptifibatide treatment in 85 patients undergoing percutaneous transluminal angioplasty
Pharmaceutical industry
Kau Pharmaceuticals, Inc. and Daiichi Sankyo Company, Limited have announced a partnership for the global development and commercialization of KAI-9803, a delta protein kinase C (delta PKC) inhibitor, for the prevention of myocardial tissue death and associated congestive heart failure in acute myocardial infarction patients. The agreement comes with significant
Pharmaceutical industry
Sangamo BioSciences, Inc. has furthered its research collaboration with Pfizer Inc by entering into a second agreement that expands the scope of their existing research collaboration in the field of enhanced protein production. Through this agreement, Pfizer will fund further research at Sangamo, leveraging the company's zinc finger
Pharmaceutical industry
Metabasis Therapeutics, Inc., a biopharmaceutical company, has strengthened its leadership team with the appointment of Howard Foyt, MD, PhD as vice president, clinical development; R. Wayne Frost, PharmD, JD as vice president, regulatory affairs and quality assurance; and Jeff Jensen as senior director, clinical operations. These additions demonstrate Metabasis'
Pharmaceutical industry
Britain's reputation as a leading centre for pharmaceutical and biotechnology research and development has been reinforced with the announcements of two major investments by Eisai and Amgen. The Japanese pharmaceutical company is building a £75m research and manufacturing centre in Hertfordshire, which will create 500 jobs, while the
Pharmaceutical industry
Athersys Inc., a Cleveland-based biotech company, is gearing up for an exciting year with multiple initiatives underway. The company is planning to begin human clinical trials for an obesity drug and a stem cell treatment for cancer patients this year. These trials, pending the success of animal and laboratory testing,
Pharmaceutical industry
A major intellectual property dispute between Dow AgroSciences and Monsanto, two of the world's leading life sciences companies, has been resolved through a cross-licensing agreement. This deal marks a significant milestone for both companies, opening up new markets for Dow AgroSciences and ending a lengthy legal battle that
Pharmaceutical industry
Avigen, a biopharmaceutical company, has reached a deal to sell its AAV gene therapy assets to Genzyme Corp. As part of the agreement, Genzyme will acquire Avigen's comprehensive AAV intellectual property (IP) portfolio, including its Parkinson's disease clinical trial program, which is currently in phase I/
Drugs
Viragen, Inc. has entered into a 10-year license agreement with Kuhnil Pharm Co. Ltd. to distribute its multi-subtype, natural human alpha interferon, Multiferon, in South Korea. Under the agreement, Kuhnil Pharm will provide exclusive marketing rights to the drug in exchange for a small up-front license fee. The South Korean
Drugs
Avigen, a biopharmaceutical company, has reached an agreement to sell its AAV gene therapy assets to Genzyme Corp. for $12 million upfront, with additional milestone payments and royalty payments on developed products. The assets include all rights to an extensive patent estate and Avigen's Parkinson's disease
